BELLEVUE, Wash.--(BUSINESS WIRE)--SCOLR Pharma, Inc. (Amex:DDD) announced today that it has achieved a development milestone which will result in a payment under its previously disclosed Development and License Agreement with Wyeth Consumer Healthcare, a division of Wyeth (NYSE:WYE). SCOLR Pharma expects to report the milestone payment as research and development revenues for the quarter ending September 30, 2006. In addition, Wyeth agreed to reimburse SCOLR for certain research and development costs already incurred and pay ongoing expenses associated with development of the first product.
